Medicines in Development for Mental Illnesses 2017 Report

PhRMA October 9, 2017

To download the full report, click here.

Biopharmaceutical research companies are developing more than 140 medicines for mental illnesses. Mental illnesses exact a heavy human and economic toll in the United States. The National Institute of Mental Health (NIMH) estimates that nearly 18 percent of American adults and 20 percent of children experience a mental illness in any given year amounting to more than $317 billion annually in the United States in lost wages, health care expenditures and disability benefits.

While the impact of mental illness is considerable, biopharmaceutical research companies have helped to alleviate some of the burden and improve the quality of life for many living with a mental illness. Recent advances have transformed certain mental illnesses into highly treatable and manageable conditions. For example, medicines for treating depression are helping millions of people live productive lives and advances in schizophrenia medicines have enabled patients to avoid hospitalization and receive treatment in an outpatient setting. 

Download Full Report